Rongcan Biotech specializes in the development and industrialization of mRNA-based medicines, positioning itself as a leader in the innovative nucleic acid therapeutics sector. The company operates a comprehensive whole-industry-chain model that encompasses nucleic acid sequential design, mRNA synthesis, and the development of delivery platforms, ultimately leading to the production of finished RNA-based pharmaceutical products. Central to their operations is the proprietary RNA-based Therapeutic Platform (RTP), which is designed for the development of mRNA-based vaccines and therapeutics. This platform allows Rongcan to address unmet medical needs by creating innovative nucleic acid medicines that can effectively regulate gene expression and protein function.

A key aspect of Rongcan's technology is its capability to develop lipid nanoparticle (LNP)-based delivery systems for mRNA and small interfering RNA (siRNA), which are crucial for ensuring optimal safety and efficacy profiles in therapeutic applications. The company utilizes in vitro transcription (IVT) methods to synthesize single-stranded mRNA from DNA templates, which carries genetic information necessary for protein synthesis. By delivering mRNA encoding specific antigens into immune cells, Rongcan's therapies can stimulate the immune system to produce targeted immune responses, thereby holding promise for the prevention and treatment of various human diseases.

China

RongCan Biotech focuses on the development and industrialization of nucleic acid-based therapeutics, striving to become a whole-industry-chain company.

Rongcan Biotech

Company Details